Finally, as upregulation of CD36 correlates with poor prognosis and survival rate in patients with different cancers, and that its amplification correlates with metastasis in many human cancers, CD36 appears to be an interesting target for the management of metastatic disease [132]. Here, CD36 is linked to cancer.